Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

I-Mab ADR (IMAB)

I-Mab ADR (IMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 378,086
  • Shares Outstanding, K 81,660
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,230 K
  • EBIT $ -40 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.92
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.36
  • Most Recent Earnings $-0.07 on 08/20/25
  • Next Earnings Date 11/13/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.08
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +76.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.46 +33.82%
on 09/30/25
6.79 -31.81%
on 10/16/25
+1.21 (+35.38%)
since 09/29/25
3-Month
1.75 +164.57%
on 07/30/25
6.79 -31.81%
on 10/16/25
+2.93 (+172.35%)
since 07/29/25
52-Week
0.60 +678.15%
on 04/04/25
6.79 -31.81%
on 10/16/25
+3.45 (+292.37%)
since 10/29/24

Most Recent Stories

More News
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global capital...

IMAB : 4.63 (-0.22%)
NBP : 4.10 (+2.76%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact...

IMAB : 4.63 (-0.22%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB). Such investors are advised to contact...

IMAB : 4.63 (-0.22%)
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025

Updated Phase 1 givastomig monotherapy data show an impressive 18% ORR in metastatic gastric cancer patients who had received at least two prior lines of therapy. Responses were observed over a dose range...

IMAB : 4.63 (-0.22%)
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients...

IMAB : 4.63 (-0.22%)
BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

BTIG analyst Justin Zelin maintained a Buy rating on I-MAB yesterday and set a price target of $7.00. The company’s shares closed yesterday at $5.79.Elevate Your Investing Strategy: Take advantage of...

IMAB : 4.63 (-0.22%)
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held October 22-26 in Boston, Massachusetts ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab...

IMAB : 4.63 (-0.22%)
I-Mab Reports H1 2025 Financial Results Amid Strategic Shift

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

IMAB : 4.63 (-0.22%)
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), I-MAB (IMAB) and Cidara Therapeutics (CDTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Maze Therapeutics, Inc. (MAZE – Research Report), I-MAB (IMAB – Research Report) and Cidara Therapeutics...

IMAB : 4.63 (-0.22%)
CDTX : 220.65 (+0.07%)
MAZE : 41.76 (-1.97%)
Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbSci (ABSI – Research Report), Soleno Therapeutics (SLNO – Research Report) and I-MAB (IMAB – Research...

IMAB : 4.63 (-0.22%)
ABSI : 3.53 (-5.36%)
SLNO : 51.24 (-2.73%)

Business Summary

I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China.

See More

Key Turning Points

3rd Resistance Point 5.05
2nd Resistance Point 4.91
1st Resistance Point 4.77
Last Price 4.63
1st Support Level 4.49
2nd Support Level 4.35
3rd Support Level 4.21

See More

52-Week High 6.79
Last Price 4.63
Fibonacci 61.8% 4.42
Fibonacci 50% 3.69
Fibonacci 38.2% 2.96
52-Week Low 0.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar